老虎证券

Corcept Soars as Ovarian Cancer Drug Succeeds Late-Stage Trial

Reuters
03-31

** Shares of drugmaker Corcept Therapeutics soar 91.4% to $104.55 premarket

** CORT says its experimental drug for ovarian cancer in combination with chemotherapy met the main goal of a late-stage trial

** Co says the drug, relacorilant, when combined with chemotherapy agent nab-paclitaxel, showed a 30% reduction in disease-progression risk in platinum-resistant ovarian cancer patients, compared to those treated with chemotherapy alone

** Platinum-resistant ovarian cancer is a type of ovarian cancer that doesn't responds to platinum-based chemotherapy treatments, which are typically used as a first-line therapy

** As of last close, CORT shares rise up 8.4% YTD

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10